BR112017028240A2 - compostos 4-(3-pirazolilamino)-benzimidazol e seu uso como inibidores de jak1 - Google Patents

compostos 4-(3-pirazolilamino)-benzimidazol e seu uso como inibidores de jak1

Info

Publication number
BR112017028240A2
BR112017028240A2 BR112017028240A BR112017028240A BR112017028240A2 BR 112017028240 A2 BR112017028240 A2 BR 112017028240A2 BR 112017028240 A BR112017028240 A BR 112017028240A BR 112017028240 A BR112017028240 A BR 112017028240A BR 112017028240 A2 BR112017028240 A2 BR 112017028240A2
Authority
BR
Brazil
Prior art keywords
pyrazolylamino
compounds
benzimidazole compounds
jak1 inhibitors
jak1
Prior art date
Application number
BR112017028240A
Other languages
English (en)
Other versions
BR112017028240B1 (pt
Inventor
Ryan Clayton Joshua
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112017028240A2 publication Critical patent/BR112017028240A2/pt
Publication of BR112017028240B1 publication Critical patent/BR112017028240B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

a presente invenção refere-se a certos compostos benzimidazol de fórmula i, ou sais farmaceuticamente aceitáveis dos mesmos, que inibem janus cinase 1 (jak1), composições farmacêuticas compreendendo os compostos e métodos de uso dos compostos para tratar certos tipos de câncer.
BR112017028240-2A 2015-08-04 2016-07-28 4-(3-pirazolilamino)-benzimidazol, seu uso, e composição farmacêutica BR112017028240B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562200684P 2015-08-04 2015-08-04
US62/200,684 2015-08-04
PCT/US2016/044410 WO2017023672A1 (en) 2015-08-04 2016-07-28 4-(3-pyrazolylamino)-benzimidazole compounds and their use as jak1 inhibitors

Publications (2)

Publication Number Publication Date
BR112017028240A2 true BR112017028240A2 (pt) 2018-09-04
BR112017028240B1 BR112017028240B1 (pt) 2023-04-11

Family

ID=56618268

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017028240-2A BR112017028240B1 (pt) 2015-08-04 2016-07-28 4-(3-pirazolilamino)-benzimidazol, seu uso, e composição farmacêutica

Country Status (27)

Country Link
US (1) US9556153B1 (pt)
EP (1) EP3331873B1 (pt)
JP (1) JP6470869B2 (pt)
KR (1) KR102032792B1 (pt)
CN (1) CN108026076B (pt)
AR (1) AR105400A1 (pt)
AU (1) AU2016302748B2 (pt)
BR (1) BR112017028240B1 (pt)
CA (1) CA2990471C (pt)
CY (1) CY1121909T1 (pt)
DK (1) DK3331873T3 (pt)
EA (1) EA033572B1 (pt)
ES (1) ES2743499T3 (pt)
HR (1) HRP20191227T1 (pt)
HU (1) HUE047037T2 (pt)
LT (1) LT3331873T (pt)
MA (1) MA44383B1 (pt)
MD (1) MD3331873T2 (pt)
ME (1) ME03451B (pt)
MX (1) MX2018001306A (pt)
NZ (1) NZ738247A (pt)
PL (1) PL3331873T3 (pt)
PT (1) PT3331873T (pt)
RS (1) RS58974B1 (pt)
SI (1) SI3331873T1 (pt)
TW (1) TW201718555A (pt)
WO (1) WO2017023672A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018013486A1 (en) * 2016-07-14 2018-01-18 Eli Lilly And Company Pyrazolylaminobenzimidazole derivatives as jak inhibitors
GB201717260D0 (en) * 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013025628A1 (en) * 2011-08-15 2013-02-21 Ligand Pharmaceuticals Incorporated Janus kinase inhibitor compounds and methods
KR20150008907A (ko) * 2012-06-14 2015-01-23 일라이 릴리 앤드 캄파니 Jak1 및 jak2의 억제제
GB201401086D0 (en) * 2014-01-23 2014-03-12 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
HRP20191227T1 (hr) 2019-10-18
JP2018524384A (ja) 2018-08-30
US9556153B1 (en) 2017-01-31
NZ738247A (en) 2019-06-28
US20170037034A1 (en) 2017-02-09
CN108026076B (zh) 2020-07-10
LT3331873T (lt) 2019-08-26
CY1121909T1 (el) 2020-10-14
RS58974B1 (sr) 2019-08-30
MX2018001306A (es) 2018-05-17
CA2990471A1 (en) 2017-02-09
CN108026076A (zh) 2018-05-11
CA2990471C (en) 2020-01-07
SI3331873T1 (sl) 2019-08-30
AU2016302748B2 (en) 2019-02-28
DK3331873T3 (da) 2019-08-12
MD3331873T2 (ro) 2019-11-30
AR105400A1 (es) 2017-09-27
ME03451B (me) 2020-01-20
ES2743499T3 (es) 2020-02-19
MA44383B1 (fr) 2019-08-30
MA44383A (fr) 2019-01-23
JP6470869B2 (ja) 2019-02-13
WO2017023672A1 (en) 2017-02-09
PL3331873T3 (pl) 2019-11-29
EA201792676A1 (ru) 2018-07-31
HUE047037T2 (hu) 2020-04-28
EP3331873B1 (en) 2019-06-26
BR112017028240B1 (pt) 2023-04-11
KR102032792B1 (ko) 2019-10-16
PT3331873T (pt) 2019-09-12
TW201718555A (zh) 2017-06-01
KR20180022966A (ko) 2018-03-06
EA033572B1 (ru) 2019-11-06
AU2016302748A1 (en) 2018-01-04
EP3331873A1 (en) 2018-06-13

Similar Documents

Publication Publication Date Title
CY1124726T1 (el) Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv
BR112016016844A2 (pt) Compostos heterocíclicos
CY1120692T1 (el) Καινοφανη παραγωγα βενζιμιδαζολης ως αναστολεις κινασων
BR112019006712A2 (pt) composto, composição farmacêutica, composição para uso no tratamento de uma doença, elemento implantável, e, dispositivo.
BR112018000624A2 (pt) compostos de indazol e azaindazol como inibidores de irak-4
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
BR112016029853A2 (pt) compostos de indazol substituído como inibidores de irak4
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
BR112016015449A8 (pt) compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
NZ726608A (en) Phosphatidylinositol 3-kinase inhibitors
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
BR112015032693A2 (pt) inibidores de bromodomínio
UY35684A (es) Formulación de inhibidores de la tirosina quinasa de bazo (syk)
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
NZ726360A (en) Phosphatidylinositol 3-kinase inhibitors
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
NZ726055A (en) Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
CO2019012571A2 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112015029495A2 (pt) compostos heterocíclicos como inibidores da via de sinalização hedgehog
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
CR20180091A (es) 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del vih

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/07/2016, OBSERVADAS AS CONDICOES LEGAIS